Back to Search
Start Over
Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
- Source :
- Blood, Blood, American Society of Hematology, 2019, 134 (3), pp.317-320. ⟨10.1182/blood.2019000658⟩, Blood, 2019, 134 (3), pp.317-320. ⟨10.1182/blood.2019000658⟩
- Publication Year :
- 2019
- Publisher :
- HAL CCSD, 2019.
-
Abstract
- TO THE EDITOR: Inhibitory antibodies (inhibitors) against factor VIII (FVIII) develop in 25% to 35% of previously untreated patients (PUPs) with severe hemophilia A (SHA). It is the most serious complication of classic hemophilia treatment.[1][1][⇓][2]-[3][3] Most inhibitors develop during the
- Subjects :
- 0301 basic medicine
congenital, hereditary, and neonatal diseases and abnormalities
medicine.medical_specialty
Letter
Time Factors
Immunology
Kaplan-Meier Estimate
Severe hemophilia A
Hemophilia A
Gastroenterology
Biochemistry
Severity of Illness Index
03 medical and health sciences
0302 clinical medicine
Isoantibodies
hemic and lymphatic diseases
Internal medicine
Severity of illness
medicine
Humans
ComputingMilieux_MISCELLANEOUS
Hematology
Blood Coagulation Factor Inhibitors
business.industry
Incidence
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Cell Biology
Inhibitory antibodies
Prognosis
3. Good health
030104 developmental biology
business
Complication
Biomarkers
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Database :
- OpenAIRE
- Journal :
- Blood, Blood, American Society of Hematology, 2019, 134 (3), pp.317-320. ⟨10.1182/blood.2019000658⟩, Blood, 2019, 134 (3), pp.317-320. ⟨10.1182/blood.2019000658⟩
- Accession number :
- edsair.doi.dedup.....afdb95deba4b03d8b01803d58f7d2f33